Endo Pharmaceuticals Receives “Buy” Rating from Bank of America (ENDP)
The analysts wrote, “ENDP shares have rallied this year (+17%) after a challenging 2012 (-24%), which has been helped in part by stable demand for “new” Opana ER despite the availability of “old” generics, market speculation that ENDP was considering a sale (as reported on Bloomberg), and the hiring of new CEO Rajiv De Silva, who was associated with shareholder value creation at VRX. Given how the stock has performed, and the fundamental changes to the business that have occurred over the past several months, we update our theoretical sum-of-the-parts (SOTP) scenario analysis, where we look at historical acquisition multiples for the sector.”
A number of other firms have also recently commented on ENDP. Analysts at Zacks upgraded shares of Endo Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note to investors on Tuesday, March 5th. They now have a $32.00 price target on the stock. Separately, analysts at TheStreet downgraded shares of Endo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note to investors on Monday, March 4th. Finally, analysts at Piper Jaffray downgraded shares of Endo Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note to investors on Monday, February 25th. They now have a $22.00 price target on the stock, down previously from $28.00.
Nine investment analysts have rated the stock with a buy rating, nine have given a hold rating, one has assigned an underweight rating, and two have given a sell rating to the company’s stock. The stock currently has an average rating of “overweight” and an average price target of $33.08.
Shares of Endo Pharmaceuticals (NASDAQ: ENDP) traded down 0.55% during mid-day trading on Monday, hitting $30.51. Endo Pharmaceuticals has a 52 week low of $25.01 and a 52 week high of $39.29. The stock’s 50-day moving average is currently $30.08. The company’s market cap is $3.386 billion.
Endo Pharmaceuticals (NASDAQ: ENDP) last announced its earnings results on Thursday, February 28th. The company reported $1.62 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.54 by $0.08. The company had revenue of $801.06 million for the quarter, compared to the consensus estimate of $807.98 million. During the same quarter last year, the company posted $1.40 earnings per share. Endo Pharmaceuticals’s revenue was down .3% compared to the same quarter last year. Endo Pharmaceuticals has set its FY13 guidance at $4.40-4.70 EPS. Analysts expect that Endo Pharmaceuticals will post $4.54 EPS for the current fiscal year.
Endo Health Solutions Inc., formerly Endo Pharmaceuticals Holdings Inc., is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.